Equities

Foghorn Therapeutics Inc.

FHTX:NMQ

Foghorn Therapeutics Inc.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.67
  • Today's Change0.11 / 1.15%
  • Shares traded126.46k
  • 1 Year change+58.78%
  • Beta3.0883
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Foghorn Therapeutics Inc. have a median target of 17.00, with a high estimate of 20.00 and a low estimate of 6.00. The median estimate represents a 75.80% increase from the last price of 9.67.
High106.8%20.00
Med75.8%17.00
Low-38.0%6.00

Earnings history & estimates in USD

On Aug 08, 2024, Foghorn Therapeutics Inc. reported 2nd quarter 2024 losses of -0.45 per share. This result exceeded the -0.66 consensus loss of the 4 analysts covering the company and exceeded last year's 2nd quarter results by 35.71%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+1.00%
Foghorn Therapeutics Inc. reported annual 2023 losses of -2.34 per share on Mar 07, 2024.
Average growth rate+23.58%
More ▼

Revenue history & estimates in USD

Foghorn Therapeutics Inc. had 2nd quarter 2024 revenues of 6.89m. This bettered the 6.04m consensus of the 5 analysts covering the company. This was 29.74% above the prior year's 2nd quarter results.
Average growth rate+42.28%
Foghorn Therapeutics Inc. had revenues for the full year 2023 of 34.16m. This was 77.63% above the prior year's results.
Average growth rate+547.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.